| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
HAMBURG, Germany—Screening specialist Evotec OAI and pharma giant Roche announced an alliance to discovery and develop therapeutics targeting CNS disorders and other indications. The two companies have been working together for several years through service and in-licensing agreements, so partnering was a logical next step, according to Dr. John Kemp, Evotec executive vice president of R&D.
 
The field could be particularly lucrative for the two companies, according to a recent Frost & Sullivan report, which suggests that European expenditures on CNS-related drugs reached $22.9 billion in 2005 and is expected to reach approximately $31.3 billion by 2012.
 
As Frost analyst Sumanth Kambhammettu explained: "The expansion of the CNS market is expected to be based on neurological disorders such as Alzheimer's disease and multiple sclerosis. Psychiatric disorders feature a high level of genericization and intense competition, resulting in a shift in focus to neurological disorders."
 
Under the terms of the agreement, the two companies will jointly take products to the clinical stage, after which time Roche will have exclusive rights to develop drug candidates. Meanwhile, Evotec will be eligible for milestone payments that could exceed €100 million, as well as royalties on the sale of marketed products. If Roche does not exercise its opt-in rights, the rights will revert to Evotec, if desired, which will make adjusted payments to Roche.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue